Literature DB >> 11396099

Systemic low-dose glucocorticoid treatment in rheumatoid arthritis.

J R Kirwan1.   

Abstract

Glucocorticoids provide a large, immediate improvement in the symptoms of rheumatoid arthritis. At doses acceptable for long-term treatment, however, symptoms gradually re-emerge. Relatively low doses of glucocorticoids can, for several years, substantially retard the rate of joint destruction shown on radiographs. This differential effect implies the coexistence of two pathologic processes within diseased joints. Long term, low dose glucocorticoid therapy probably increases the risk of serious adverse effects, but an evidence-based case can be made for the limited use of low dose glucocorticoid treatment in early disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11396099     DOI: 10.1016/s0889-857x(05)70208-8

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  5 in total

1.  Radiological damage in patients with rheumatoid arthritis on sustained remission.

Authors:  G Cohen; L Gossec; M Dougados; A Cantagrel; P Goupille; J P Daures; N Rincheval; B Combe
Journal:  Ann Rheum Dis       Date:  2006-08-25       Impact factor: 19.103

Review 2.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Vokko P van Halm; Ben A C Dijkmans
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Effective use of TNF antagonists.

Authors:  David Yocum
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

Review 5.  Atherogenic lipid profiles and its management in patients with rheumatoid arthritis.

Authors:  Michael T Nurmohamed
Journal:  Vasc Health Risk Manag       Date:  2007
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.